HRP20231457T1 - Liječenje lag-3-pozitivnih tumora - Google Patents

Liječenje lag-3-pozitivnih tumora Download PDF

Info

Publication number
HRP20231457T1
HRP20231457T1 HRP20231457TT HRP20231457T HRP20231457T1 HR P20231457 T1 HRP20231457 T1 HR P20231457T1 HR P20231457T T HRP20231457T T HR P20231457TT HR P20231457 T HRP20231457 T HR P20231457T HR P20231457 T1 HRP20231457 T1 HR P20231457T1
Authority
HR
Croatia
Prior art keywords
antibody
cancer
lag
inhibitor
seq
Prior art date
Application number
HRP20231457TT
Other languages
English (en)
Croatian (hr)
Inventor
James Novotny Jr.
Nils Lonberg
Cyrus HEDVAT
Raphael Clynes
Darren LOCKE
John P. Cogswell
Jeffrey Jackson
Christopher Harbison
Robin EDWARDS
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62778996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231457(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20231457T1 publication Critical patent/HRP20231457T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • G01N33/5751—
    • G01N33/5758—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HRP20231457TT 2017-05-30 2018-05-30 Liječenje lag-3-pozitivnih tumora HRP20231457T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762512648P 2017-05-30 2017-05-30
US201762513813P 2017-06-01 2017-06-01
US201762555176P 2017-09-07 2017-09-07
US201762582178P 2017-11-06 2017-11-06
EP18735009.5A EP3631454B1 (en) 2017-05-30 2018-05-30 Treatment of lag-3 positive tumors
PCT/US2018/035134 WO2018222718A1 (en) 2017-05-30 2018-05-30 Treatment of lag-3 positive tumors

Publications (1)

Publication Number Publication Date
HRP20231457T1 true HRP20231457T1 (hr) 2024-05-10

Family

ID=62778996

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231457TT HRP20231457T1 (hr) 2017-05-30 2018-05-30 Liječenje lag-3-pozitivnih tumora

Country Status (22)

Country Link
US (3) US11807686B2 (cg-RX-API-DMAC7.html)
EP (2) EP3631454B1 (cg-RX-API-DMAC7.html)
JP (3) JP2020522691A (cg-RX-API-DMAC7.html)
KR (3) KR20240146108A (cg-RX-API-DMAC7.html)
CN (1) CN110720039A (cg-RX-API-DMAC7.html)
AU (2) AU2018277824A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020610A2 (cg-RX-API-DMAC7.html)
CA (1) CA3060984A1 (cg-RX-API-DMAC7.html)
DK (1) DK3631454T3 (cg-RX-API-DMAC7.html)
ES (1) ES2965352T3 (cg-RX-API-DMAC7.html)
FI (1) FI3631454T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231457T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065242T2 (cg-RX-API-DMAC7.html)
IL (2) IL322104A (cg-RX-API-DMAC7.html)
LT (1) LT3631454T (cg-RX-API-DMAC7.html)
MX (2) MX2019012032A (cg-RX-API-DMAC7.html)
PL (1) PL3631454T3 (cg-RX-API-DMAC7.html)
PT (1) PT3631454T (cg-RX-API-DMAC7.html)
RS (1) RS64787B1 (cg-RX-API-DMAC7.html)
SI (1) SI3631454T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300418T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018222718A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
DK3631454T3 (da) 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer
WO2019018730A1 (en) * 2017-07-20 2019-01-24 Novartis Ag DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
CA3107660A1 (en) * 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
US20210403557A1 (en) * 2018-11-05 2021-12-30 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
BR112021022831A2 (pt) * 2019-05-14 2022-01-18 F Star Therapeutics Ltd Regimes de dosagem para a administração de um anticorpo biespecífico lag-3/pd-l1
WO2021030156A1 (en) * 2019-08-09 2021-02-18 The Regents Of The University Of California Compositions and methods for diagnosis and treatment of bladder cancer
US20220348653A1 (en) * 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
CN114630679A (zh) * 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
CN115942973A (zh) * 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
CN113616788A (zh) * 2020-05-08 2021-11-09 勤浩医药（苏州）有限公司 抗lag-3抗体与shp-2抑制剂联合治疗肿瘤的用途
EP4157879A4 (en) * 2020-05-27 2024-06-19 Agilent Technologies, Inc. Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc)
CA3193421A1 (en) * 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
WO2023051621A1 (zh) * 2021-09-29 2023-04-06 中山康方生物医药有限公司 抗lag3抗体、药物组合物及用途
CN114869877B (zh) * 2022-01-26 2024-05-31 兰州大学 一种小分子化合物及其作为lag3蛋白抑制剂的应用

Family Cites Families (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1081681A (en) 1910-08-31 1913-12-16 Otis Elevator Co Alternating-current-motor control.
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ZA953629B (en) 1994-05-06 1996-11-05 Roussy Inst Gustave Soluble polypeptidic fragments of lag-3 protein method of production thereof therapeutic composition anti-idiotype antibodies
JP2000508226A (ja) 1995-07-21 2000-07-04 アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1997032733A1 (en) 1996-03-07 1997-09-12 Eastman Chemical Company Near infrared fluorescent security thermal transfer printing and marking ribbons
AU728911B2 (en) 1996-11-28 2001-01-18 Institut Gustave Roussy Mutants of the LAG-3 proteins, products for the expression of these mutants and use
US6500422B2 (en) 1996-11-29 2002-12-31 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (LAG-3)
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
EP0900841A1 (en) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
KR100617337B1 (ko) 1998-12-23 2006-08-31 화이자 인크. Ｃｔｌａ－４에 대한 인간 단일클론 항체
GB9911569D0 (en) 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
WO2002074903A2 (en) 2001-02-22 2002-09-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20020146753A1 (en) 2001-04-06 2002-10-10 Henrik Ditzel Autoantibodies to glucose-6-phosphate isomerase and their participation in autoimmune disease
ATE519779T1 (de) 2001-09-19 2011-08-15 Roussy Inst Gustave An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
JP4439262B2 (ja) 2001-09-19 2010-03-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ535925A (en) 2002-04-16 2008-06-30 Genentech Inc An isolated antibody that binds to a particular polypeptide
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
WO2004007520A2 (en) 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
WO2005035732A2 (en) 2003-02-19 2005-04-21 Dyax Corporation Papp-a ligands
EP1897548B2 (en) 2003-02-28 2024-05-22 The Johns Hopkins University T cell regulation
WO2005034733A2 (en) 2003-10-08 2005-04-21 North Shore-Long Island Jewish Research Institute Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia
PL2418220T3 (pl) 2003-12-10 2017-12-29 E. R. Squibb & Sons, L.L.C. Przeciwciała przeciwko interferonowi alfa i ich zastosowania
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
EP2374817B1 (en) 2004-04-13 2017-09-06 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
CA2582016A1 (en) 2004-10-01 2006-04-13 Medarex, Inc. Methods of treating cd30 positive lymphomas
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
RU2007134867A (ru) 2005-03-23 2009-04-27 Пфайзер Продактс Инк. (Us) Терапия рака предстательной железы ctla4-антителами и гормональной терапией
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP2314619A1 (en) 2005-12-05 2011-04-27 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
CN101490085A (zh) 2006-06-12 2009-07-22 特鲁比昂药品公司 具有效应功能的单链多价结合蛋白
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
CA2932012A1 (en) 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
JP5456658B2 (ja) 2007-03-30 2014-04-02 メディミューン，エルエルシー 抗体製剤
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
HUE029164T2 (hu) 2007-09-14 2017-02-28 Univ Brussel Vrije Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
US20110007023A1 (en) 2009-07-09 2011-01-13 Sony Ericsson Mobile Communications Ab Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
SG10201704269RA (en) 2009-07-15 2017-06-29 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20130115227A1 (en) 2010-07-14 2013-05-09 Renee C. Gaspar Anti-addl monoclonal antibody and uses thereof
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
EP2635605B1 (en) 2010-11-01 2018-07-25 Symphogen A/S Anti-her3 antibodies and compositions
KR20190116563A (ko) 2011-03-31 2019-10-14 머크 샤프 앤드 돔 코포레이션 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
EP2734551B1 (en) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
CA2853637C (en) 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
US9689876B2 (en) 2012-05-02 2017-06-27 New York University Methods related to cancer treatment
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102163408B1 (ko) 2012-05-31 2020-10-08 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3404116B1 (en) 2013-03-15 2022-10-19 The University of Chicago Methods and compositions related to t-cell activity
IL240838B (en) 2013-03-15 2022-09-01 Glaxosmithkline Ip Dev Ltd Anti-3–lag binding proteins
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
JP2016531907A (ja) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
US20160312295A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
CN105934253A (zh) 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
EP3084005A4 (en) 2013-12-17 2017-08-02 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EP3099716A1 (en) 2014-01-28 2016-12-07 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
UY36032A (es) * 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
CA2946606C (en) 2014-05-13 2023-06-06 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
EA201790834A1 (ru) * 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
WO2016127220A1 (en) 2015-02-13 2016-08-18 The University Of Queensland Methods for classifying tumors and uses therefor
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
PL3319635T3 (pl) * 2015-06-24 2021-10-25 Immodulon Therapeutics Limited Inhibitor punktu kontrolnego i prątek całokomórkowy do stosowania w terapii nowotworowej
EP3314020A1 (en) 2015-06-29 2018-05-02 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
CN108348601B (zh) 2015-07-22 2022-05-17 索伦托药业有限公司 与lag3结合的抗体治疗剂
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
SMT202100527T1 (it) 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EA201890456A1 (ru) 2015-08-07 2018-07-31 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN108136216B (zh) 2015-10-23 2021-08-24 诺华股份有限公司 对包含肿瘤组织的样品评分的方法
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
JP6931329B2 (ja) 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
KR102220275B1 (ko) 2015-11-18 2021-02-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
JP6983776B2 (ja) * 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
US10969392B2 (en) 2015-12-10 2021-04-06 Vanderbilt University Methods and systems for predicting response to immunotherapies for treatment of cancer
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
AU2016371639A1 (en) 2015-12-16 2018-06-28 Merck Sharp & Dohme Llc Anti-LAG3 antibodies and antigen-binding fragments
US11814679B2 (en) 2016-01-11 2023-11-14 Eli Lilly And Company Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same
CN111491362B (zh) 2016-02-02 2023-10-24 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
UA127200C2 (uk) 2016-05-18 2023-06-07 Бьорінгер Інгельхайм Інтернаціональ Гмбх Молекула антитіла до pd1
AU2017283181B2 (en) 2016-06-20 2024-08-15 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
CA3027302A1 (en) 2016-06-20 2017-12-28 F-Star Beta Limited Binding members(1)
KR102497259B1 (ko) 2016-06-23 2023-02-07 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Ｌａｇ―３ 항체, 이의 항원-결합 단편 및 이의 약학적 용도
RU2744866C2 (ru) 2016-08-15 2021-03-16 Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити Антитело против lag-3
JP2019529437A (ja) * 2016-09-20 2019-10-17 メディミューン，エルエルシー 抗ｐｄ−ｌ１抗体単独療法に対する固形腫瘍の奏効性を特徴付けるための組成物および方法
TWI843168B (zh) 2016-10-11 2024-05-21 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
CN117567623A (zh) 2016-10-13 2024-02-20 正大天晴药业集团股份有限公司 抗lag-3抗体及组合物
US20190300967A1 (en) 2016-10-13 2019-10-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
KR102660715B1 (ko) 2017-02-10 2024-04-26 리제너론 파마슈티칼스 인코포레이티드 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
EP3615572A1 (en) 2017-04-27 2020-03-04 Tesaro Inc. Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
EP3621642B1 (en) 2017-05-10 2024-09-18 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against lag3 and uses thereof
EP4509132A3 (en) 2017-05-26 2025-11-19 The Johns Hopkins University Multifunctional antibody-ligand traps to modulate immune tolerence
WO2018222711A2 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
DK3631454T3 (da) 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
CA3107660A1 (en) 2018-07-26 2020-01-30 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
PT4445958T (pt) 2018-10-19 2025-11-26 Bristol Myers Squibb Co Terapia de associação para melanoma
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
CN115942973A (zh) 2019-11-08 2023-04-07 百时美施贵宝公司 用于黑色素瘤的lag-3拮抗剂疗法
CA3193421A1 (en) 2020-08-28 2022-03-03 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma

Also Published As

Publication number Publication date
IL269027A (en) 2019-10-31
US20250043006A1 (en) 2025-02-06
PL3631454T3 (pl) 2024-01-29
AU2018277824A1 (en) 2019-10-17
JP2025134762A (ja) 2025-09-17
US20210261666A1 (en) 2021-08-26
MX2019012032A (es) 2019-10-30
SI3631454T1 (sl) 2023-12-29
PT3631454T (pt) 2023-11-23
SMT202300418T1 (it) 2024-01-10
US20240092911A1 (en) 2024-03-21
JP2020522691A (ja) 2020-07-30
HUE065242T2 (hu) 2024-05-28
KR20240146108A (ko) 2024-10-07
RS64787B1 (sr) 2023-11-30
KR102713203B1 (ko) 2024-10-10
AU2025200288A1 (en) 2025-02-20
IL322104A (en) 2025-09-01
EP4306542A2 (en) 2024-01-17
KR20200010501A (ko) 2020-01-30
JP2023139047A (ja) 2023-10-03
DK3631454T3 (da) 2023-12-04
WO2018222718A1 (en) 2018-12-06
CN110720039A (zh) 2020-01-21
ES2965352T3 (es) 2024-04-12
CA3060984A1 (en) 2018-12-06
EP3631454B1 (en) 2023-09-13
EP4306542A3 (en) 2024-04-17
US11807686B2 (en) 2023-11-07
EP3631454A1 (en) 2020-04-08
BR112019020610A2 (pt) 2020-04-22
US12049503B2 (en) 2024-07-30
LT3631454T (lt) 2023-11-27
FI3631454T3 (fi) 2023-11-30
KR20250165687A (ko) 2025-11-26
MX2024000054A (es) 2024-02-20

Similar Documents

Publication Publication Date Title
HRP20231457T1 (hr) Liječenje lag-3-pozitivnih tumora
JP2018027952A5 (cg-RX-API-DMAC7.html)
JP2020522691A5 (cg-RX-API-DMAC7.html)
RU2346702C2 (ru) Применение антител к ctla-4
JP2018524300A5 (ja) 組成物、抗体および結合性フラグメント
JP2021102627A5 (cg-RX-API-DMAC7.html)
JP2020055853A5 (cg-RX-API-DMAC7.html)
HRP20240926T1 (hr) Claudin-6-specifični imunoreceptori i epitopi t stanica
RU2018100545A (ru) Способы и антитела для модуляции иммунного ответа
RU2010135087A (ru) Многоклональные антитела человека к белку программируемой смерти 1 (pd) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
JP2020522495A5 (cg-RX-API-DMAC7.html)
JP2019533981A5 (cg-RX-API-DMAC7.html)
JP2020522486A5 (cg-RX-API-DMAC7.html)
RU2016104880A (ru) Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
JP2018509175A5 (cg-RX-API-DMAC7.html)
JP2020528750A5 (cg-RX-API-DMAC7.html)
RU2016146993A (ru) Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
JP2016537383A5 (cg-RX-API-DMAC7.html)
NZ752294A (en) Cd3 binding antibodies
HRP20201334T1 (hr) Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
JP2012500814A5 (cg-RX-API-DMAC7.html)
JP2007530526A5 (cg-RX-API-DMAC7.html)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2011157397A5 (cg-RX-API-DMAC7.html)
HRP20221226T1 (hr) Protutijela protiv pd-1 i postupci njihove upotrebe